ClearPoint Neuro, Inc. (CLPT) News
Follow ClearPoint Neuro, Inc. (CLPT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ClearPoint Neuro Reports Third-Quarter 2026 Results
Revenue rose 36% to $12.1 million from $8.9 million a year earlier. Net loss widened to $7.5 million from $5.9 million, and diluted loss per share was $(0.24) versus $(0.21).
EQUITY | Oct 28, 2026, 09:31 PM UTC
M
ClearPoint Neuro Sees FY Revenue at $48–50 Million
EARNINGS | Oct 28, 2026, 08:17 PM UTC
M
ClearPoint Neuro to Announce Third-Quarter 2026 Results October 28
EQUITY | Oct 14, 2026, 08:05 PM UTC
H
Crude Oil Down Over 5%; McDonald's Earnings Top Views
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 2% on Tuesday. The Dow traded up 1.79% to 54,129.35 while the NASDAQ rose 2.22% to 26,490.24. The S&P 500 also rose, gaining, 1.64%
EARNINGS | Aug 04, 2026, 04:55 PM UTC
L
Powell Industries Posts Downbeat Q3 Results, Joins Clearpoint Neuro, Ichor Holdings And Other Big Stocks Moving Lower In Tuesday’s Pre-Marke
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 150 points on Tuesday. Shares of Powell Industries Inc (NASDAQ: POWL ) fell sharply in pre-market trading after the company reported
EARNINGS | Aug 04, 2026, 12:04 PM UTC
H
Why Palantir Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving Premarket
Shares of Palantir Technologies Inc (NASDAQ: PLTR ) rose sharply in pre-market trading, after the company posted upbeat financial results for the second quarter and raised its FY26 sales guidance. Palantir reported secon
EARNINGS | Aug 04, 2026, 08:42 AM UTC
L
ClearPoint Neuro Lowers FY2026 Sales Guidance from $52.000M-$56.000M to $48.000M-$52.000M vs $53.133M Est
ClearPoint Neuro (NASDAQ: CLPT ) lowers FY2026 sales outlook from $52.000 million-$56.000 million to $48.000 million-$52.000 million vs $53.133 million estimate.
EARNINGS | Aug 03, 2026, 08:12 PM UTC
L
CLPT - ClearPoint Neuro Reports Second Quarter 2026 Results
CLPT - ClearPoint Neuro Reports Second Quarter 2026 Results
EARNINGS | Aug 03, 2026, 08:05 PM UTC
H
earnings calendar: • earnings before the open: abtc alx ava cgen cna cnh dea hesm kos krys l lind Mar mmyt plow sbh srad tgtx tsn twst • ear
earnings calendar: • earnings before the open: abtc alx ava cgen cna cnh dea hesm kos krys l lind Mar mmyt plow sbh srad tgtx tsn twst • earnings after the close: adtn adus aeis aesi alg alsn amrc ande are blze bsm bwxt
EARNINGS | Aug 03, 2026, 10:55 AM UTC
L
CLPT - ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasine
CLPT - ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
REGULATION | Jul 31, 2026, 08:05 PM UTC